SOMERVILLE, Mass. — Tessera Therapeutics (“Tessera”), the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, is presenting updates across its in vivo genetic medicine programs for SCD and T cell therapies, including its proprietary delivery platform that enables extra-hepatic LNP delivery to hematopoietic stem cells (HSCs)...

SEONGNAM, South Korea — SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer agent, in patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This multi-center...

HONG KONG — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. The abstract is now available on the EHA...